Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$251.27−1.73 (-0.68%)
Close on Oct 30, 2026Market cap $15.57BP/E 20.3Yield –
Earnings
Ascendis Pharma A/S's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 11, 2026
Q3 FY2026 · estimated, after the close
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Ascendis Pharma A/S's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 11, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 11, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 12, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Sep 3, 2024after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 7, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Sep 5, 2023after the close | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 27, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 16, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022after the close | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 2, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Ascendis Pharma A/S has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Ascendis Pharma A/S puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Ascendis Pharma A/S filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K